亦诺微完成1.02亿人民币A+轮融资  鸣笛起航原创溶瘤产品临床研究 | 新闻稿

研发客 研发客 2019-01-31




2019年1月31日,亦诺微医药正式宣布完成1500万美元A+轮融资。此次融资由业内一知名投资机构领投,幂方资本、力合科创 、薄荷天使基金跟投,A轮股东泰福资本、勤智资本和涌铧投资继续参与此轮增资。

 

本轮融资将用于亦诺微首个产品T3和T2的临床研究,以及新产品的开发。这是继获得国家十三五重大新药创制资助后,亦诺微医药在原创溶瘤病毒研发的道路上的重要里程碑。

 

“疱疹病毒之父”Bernard Roizman教授


深圳亦诺微医药科技有限公司于2015年5月在深圳创立。公司创始人为被誉为“疱疹病毒之父”的芝加哥大学Bernard Roizman教授和其弟子周国瑛博士。Bernard Roizman教授是美国FDA目前唯一批准上市的溶瘤病毒产品Imlygic(T-vec)的骨架发明人。周国瑛教授是靶向疱疹溶瘤病毒的国际发明人。

 

亦诺微医药创始人、CEO周国瑛博士


公司共同创始人包括:普林斯顿大学病毒学教授Thomas Shenk博士、启动溶瘤病毒临床研究的阿拉巴马大学Richard Whitley教授、首推溶瘤病毒与放疗联合治疗的芝加哥大学Ralph Weichselbaum教授及从事免疫学研究的芝加哥大学倪东耀研究员,其中Ralph Weichselbaum教授在2018年的ASCO大会上获得David A. Karnofsky 纪念大奖。

 

亦诺微医药创始人、董事长Bernard Roizman教授表示:“我们非常荣幸获得生物医药顶级投资机构的支持,这反映了资本市场对亦诺微发展战略、商业模式、创始团队的科学背景、产品管线的高度认可。本次融资将大大促进公司产品进入临床研究的进程。”

 

"本轮融资的顺利完成,在略显寒冷的资本市场,给亦诺微添了一把冬天里的火”,亦诺微医药创始人、CEO周国瑛博士表示:“我们将一如既往地、专业与专注地把自己的事情做好。既保持严谨的科学态度,又大胆进取,培养有创造力的员工,开发创新的产品管线,开展有效安全的临床研究。”


关于亦诺微医药

亦诺微医药致力于新一代溶瘤病毒的开发,在提高病毒复制能力的同时,进一步提高病毒溶瘤活性,以及更好的免疫应答。公司自主研发的溶瘤病毒产品T3和T2即将在美国、澳洲和中国开启临床研究,探索多种实体肿瘤的治疗。同时公司还在进行多个溶瘤病毒产品的开发,将形成一系列满足不同肿瘤治疗的强大管线,包括特异性靶向溶瘤病毒的开发。

更多信息请浏览: www.immvira-theravir.com/




Immvira Announces US$15 Million Series A+ Fundraising to Advance oHSV Clinical Studies

 

January 31, 2019/ Immvira has announced today that it has closed its Round A+ fundraising of $15 million U.S. dollars. The lead investor is a premium global investment firm, together with Mefund Capital, Leaguer Group Co., Ltd, Bohe Angel, and with additional investment from investors in previous funding round (Round A), including Taifu Capital, Triwise Capital and Yonghua Capital. This investment will be used to initiate clinical study of current product T3 which is a single therapeutic agent of three distinct cancer therapies: the targeting of cancer cells by oncolytic viruses, the stimulation of immune system by IL12, and the production of immunotherapeutic antibodies against PD-1. This investment will also be used to extend oHSV pipelines and platforms as well.

 

Immvira was founded in Shenzhen China in May of 2015 by Prof. Bernard Roizman of the University of Chicago. Prof. Grace Zhou formerly a Research Associate Professor at University of Chicago, Prof. Thomas Shenk of Princeton University, Prof. Richard Whitley of the University of Alabama, and Prof. Ralph Weichselbaum of the University of Chicago. Immvira closed its Round A fundraising of 50 Million RMB in September 2016 to develop independently the first two products T2 and T3, which to be conduct clinical trials in US, Australia and China soon.

 

Professor Bernard Roizman, the founder and chairman of Immvira said, “We are very honored to receive the support of top bio-pharmaceutical investment institutions, reflecting the recognition to our scientific background, product pipeline, development strategy and business model as well. It will greatly facilitate the process of clinical research of Immvira products."

 

 "The successful completion of this round of financing, especially in the cool capital market, has added a fire to Immvira." Dr. Grace Zhou the founder and CEO of Immvira said, “We will continually maintain rigorous scientific attitude, secure our future by creating a company of inspiring people, building innovative pipelines and conducting productive clinical studies.


Immvira

Immvira is developing a broad range of anti-cancer therapeutic pipelines including tumor-specific target oncologic viruses by creating products of engineered oncolytic HSV (oHSV) carry single or combination of immunostimulatory or/and checkpoint blockage, which target solid tumors through local or systemic delivery in mechanism of tumor-target lysis and tumor-killing immune responses, also developing a potent oncolytic platform suitable in combination with adjunct therapies.




文章已于修改
    阅读原文

    发送中

    本站仅按申请收录文章,版权归原作者所有
    如若侵权,请联系本站删除
    觉得不错,分享给更多人看到